Vivimed Labs Ltd

Vivimed Labs Ltd’s share price declined to a fresh 52-week low of ₹5.53 on 27 Mar 2026, marking a significant downturn for the micro-cap stock. The price drop reflects ongoing pressures on the company’s financial health and market performance, with the stock underperforming its sector and broader indices amid challenging conditions.

At Rs 5.55, sellers were still queuing — but there were no buyers willing to take the other side. Vivimed Labs Ltd locked at its lower circuit of 4.97% on 27 Mar 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

After a prolonged decline, Vivimed Labs Ltd touched a fresh 52-week low of Rs 5.7 on 25 Mar 2026, marking a significant drop from its 52-week high of Rs 23.94. This decline comes despite a flat one-year price performance and a broader market rally, highlighting stock-specific pressures that have weighed heavily on investor sentiment.

For the fourth consecutive session, Vivimed Labs Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 6 on 24 Mar 2026. This marks a significant drop from its 52-week high of Rs 23.94, reflecting a sustained period of selling pressure despite a flat annual return.

Vivimed Labs Ltd’s share price declined to a fresh 52-week low of Rs.6.03 on 23 Mar 2026, marking a significant downturn amid a broader market slump. The stock has been under pressure for several sessions, reflecting ongoing concerns about the company’s financial health and valuation metrics.

Vivimed Labs Ltd’s share price declined to a fresh 52-week low of Rs.6.1 on 20 Mar 2026, marking a significant downturn amid persistent financial headwinds and subdued market performance. The stock has underperformed its sector and broader indices despite a rising Sensex, reflecting ongoing concerns about the company’s financial health and valuation metrics.

Vivimed Labs Ltd’s share price declined sharply to a new 52-week low of Rs.6.31 on 19 Mar 2026, marking a significant drop amid broader market weakness and company-specific financial pressures.

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 05 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Vivimed Labs Ltd has touched a new 52-week low of Rs.6.45 today, marking a significant decline in its stock price amid ongoing financial headwinds and subdued market performance. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial metrics and valuation.

Vivimed Labs Ltd has declined to a new 52-week low, closing just 0.3% above its lowest price of Rs 6.58. The stock has underperformed its sector and broader market indices, reflecting ongoing concerns about the company’s financial health and market positioning.

Vivimed Labs Ltd witnessed a robust rally on 11 Mar 2026, hitting its upper circuit limit with a 4.98% gain to close at ₹7.17. This surge was driven by intense buying interest, resulting in a regulatory freeze on further transactions and highlighting significant unfilled demand in the market.

Vivimed Labs Ltd witnessed a robust surge in its share price on 10 Mar 2026, hitting the upper circuit limit of 7.12, marking a maximum daily gain of 2.8%. This sharp rally was driven by intense buying interest, resulting in a regulatory freeze on further transactions and leaving a significant unfilled demand in the market.

Vivimed Labs Ltd has touched a new 52-week low price of Rs.6.58 today, marking a significant decline from its 52-week high of Rs.23.94. The stock’s performance over the past year has been stagnant, with a return of 0.00%, contrasting with the Sensex’s 5.07% gain during the same period.

Vivimed Labs Ltd surged to hit its upper circuit limit on 6 March 2026, propelled by robust buying interest and a maximum daily gain of 3.94%. The stock closed at ₹7.38, near its high of ₹7.45, signalling intense demand despite a subdued broader market environment.

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 05 February 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with the latest insights into its performance and outlook.

Vivimed Labs Ltd witnessed a robust rally on 5 March 2026, hitting its upper circuit price limit as strong buying momentum propelled the stock to a maximum daily gain of 2.6%. This surge comes despite the company’s challenging fundamentals and a recent downgrade in its Mojo Grade, underscoring the complex dynamics at play in this micro-cap pharmaceutical stock.